Log in

NASDAQ:OTLK - Outlook Therapeutics Stock Price, Forecast & News

$0.94
-0.06 (-6.00 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$0.89
Now: $0.94
$0.98
50-Day Range
$0.52
MA: $0.91
$1.08
52-Week Range
$0.52
Now: $0.94
$10.88
Volume625,522 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:OTLK
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees56
Next Earnings Date5/20/2020 (Estimated)
OptionableNot Optionable

Receive OTLK News and Ratings via Email

Sign-up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.


Outlook Therapeutics (NASDAQ:OTLK) Frequently Asked Questions

What is Outlook Therapeutics' stock symbol?

Outlook Therapeutics trades on the NASDAQ under the ticker symbol "OTLK."

When did Outlook Therapeutics' stock split? How did Outlook Therapeutics' stock split work?

Outlook Therapeutics's stock reverse split on the morning of Monday, March 18th 2019. The 1-8 reverse split was announced on Friday, March 15th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 15th 2019. An investor that had 100 shares of Outlook Therapeutics stock prior to the reverse split would have 13 shares after the split.

How were Outlook Therapeutics' earnings last quarter?

Outlook Therapeutics, Inc. (NASDAQ:OTLK) posted its earnings results on Thursday, December, 19th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.19. The company earned $5.85 million during the quarter, compared to analysts' expectations of $0.63 million. View Outlook Therapeutics' Earnings History.

When is Outlook Therapeutics' next earnings date?

Outlook Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May 20th 2020. View Earnings Estimates for Outlook Therapeutics.

What price target have analysts set for OTLK?

5 brokers have issued twelve-month price targets for Outlook Therapeutics' stock. Their forecasts range from $4.00 to $12.00. On average, they expect Outlook Therapeutics' share price to reach $9.00 in the next year. This suggests a possible upside of 857.4% from the stock's current price. View Analyst Price Targets for Outlook Therapeutics.

What is the consensus analysts' recommendation for Outlook Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Outlook Therapeutics.

Has Outlook Therapeutics been receiving favorable news coverage?

News articles about OTLK stock have trended somewhat positive on Sunday, according to InfoTrie. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Outlook Therapeutics earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Outlook Therapeutics.

Are investors shorting Outlook Therapeutics?

Outlook Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,600,000 shares, an increase of 30.0% from the January 15th total of 2,000,000 shares. Based on an average trading volume of 959,100 shares, the short-interest ratio is presently 2.7 days. Approximately 21.4% of the company's shares are short sold. View Outlook Therapeutics' Current Options Chain.

What other stocks do shareholders of Outlook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include AzurRx BioPharma (AZRX), Onconova Therapeutics (ONTX), SCYNEXIS (SCYX), Acasti Pharma (ACST), Biocept (BIOC), Nabriva Therapeutics (NBRV), vTv Therapeutics (VTVT), Co-Diagnostics (CODX), Inovio Pharmaceuticals (INO) and VBI Vaccines (VBIV).

Who are Outlook Therapeutics' key executives?

Outlook Therapeutics' management team includes the folowing people:
  • Mr. Lawrence A. Kenyon, Pres, CEO, CFO, Company Sec., Treasurer & Director (Age 53)
  • Dr. Pankaj Mohan, Founder & Director (Age 54)
  • Dr. Kenneth M. Bahrt, Chief Medical Officer (Age 66)
  • Mr. Terry Dagnon, Chief Operating Officer (Age 57)
  • Rick Gregory, Director of Marketing & Communications

Who are Outlook Therapeutics' major shareholders?

Outlook Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include LVW Advisors LLC (1.45%). Company insiders that own Outlook Therapeutics stock include Kurt J Hilzinger, Lawrence A Kenyon and Randy H Thurman. View Institutional Ownership Trends for Outlook Therapeutics.

Which major investors are buying Outlook Therapeutics stock?

OTLK stock was acquired by a variety of institutional investors in the last quarter, including LVW Advisors LLC. Company insiders that have bought Outlook Therapeutics stock in the last two years include Kurt J Hilzinger, Lawrence A Kenyon and Randy H Thurman. View Insider Buying and Selling for Outlook Therapeutics.

How do I buy shares of Outlook Therapeutics?

Shares of OTLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Outlook Therapeutics' stock price today?

One share of OTLK stock can currently be purchased for approximately $0.94.


MarketBeat Community Rating for Outlook Therapeutics (NASDAQ OTLK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  168
MarketBeat's community ratings are surveys of what our community members think about Outlook Therapeutics and other stocks. Vote "Outperform" if you believe OTLK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTLK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Featured Article: Cost of Debt

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel